The unique metabolic features of cancer cells offer potential therapeutic targets. Agents that inhibit glycolysis, such as 2-deoxyglucose, or drugs targeting key metabolic enzymes like IDH inhibitors can selectively affect cancer cell metabolism. Additionally, disrupting glutamine metabolism or inhibiting lipid synthesis are promising strategies under investigation in preclinical and clinical studies.
